Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$131.81
+0.0%
$129.00
$64.09
$131.88
$14.04B0.691.39 million shs1.58 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$31.12
-3.1%
$34.78
$29.25
$170.47
$12.03B1.866.81 million shs5.68 million shs
Organon & Co. stock logo
OGN
Organon & Co.
$14.52
-0.3%
$15.36
$13.87
$23.10
$3.74B0.762.54 million shs1.87 million shs
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
$20.32
-1.4%
$20.49
$2.10
$33.89
$14.99B-1.043.43 million shs1.69 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
+0.05%+0.11%+2.51%+55.27%+88.97%
Moderna, Inc. stock logo
MRNA
Moderna
+2.03%-1.02%-3.30%-19.96%-70.96%
Organon & Co. stock logo
OGN
Organon & Co.
-0.95%-6.72%-9.95%-3.29%-21.06%
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
+3.57%+5.97%+13.75%+13.12%+449.33%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
3.6029 of 5 stars
2.23.00.04.53.01.70.6
Moderna, Inc. stock logo
MRNA
Moderna
4.0928 of 5 stars
4.01.00.04.61.32.50.6
Organon & Co. stock logo
OGN
Organon & Co.
4.755 of 5 stars
3.21.03.33.73.01.73.1
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
2.8149 of 5 stars
4.52.00.00.02.51.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.47
Hold$106.08-19.52% Downside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$59.0089.59% Upside
Organon & Co. stock logo
OGN
Organon & Co.
2.43
Hold$20.8043.30% Upside
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
3.00
Buy$35.4474.43% Upside

Current Analyst Ratings Breakdown

Latest OGN, SMMT, ITCI, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/26/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$23.00 ➝ $35.00
3/21/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
3/21/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
3/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
3/12/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$30.00
2/28/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$42.00
2/25/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$44.00 ➝ $44.00
2/24/2025
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$140.00 ➝ $132.00
2/21/2025
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
2/19/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$96.00 ➝ $78.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$40.00 ➝ $40.00
(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$680.50M20.63N/AN/A$6.15 per share21.43
Moderna, Inc. stock logo
MRNA
Moderna
$3.20B3.76N/AN/A$28.33 per share1.10
Organon & Co. stock logo
OGN
Organon & Co.
$6.40B0.58$4.65 per share3.12($0.27) per share-53.76
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
$700K21,413.80N/AN/A$0.11 per share184.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$139.67M-$0.73N/A693.74N/A-14.07%-9.93%-8.38%5/6/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$9.28N/AN/AN/A-110.04%-28.74%-21.83%5/1/2025 (Estimated)
Organon & Co. stock logo
OGN
Organon & Co.
$864M$3.334.363.880.9013.49%431.62%8.03%5/1/2025 (Estimated)
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
-$614.93M-$0.31N/AN/AN/AN/A-85.42%-52.66%4/29/2025 (Estimated)

Latest OGN, SMMT, ITCI, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/24/2025Q4 2024
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
-$0.08-$0.08N/A-$0.08N/A$0.20 million
2/21/2025Q4 2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$0.08-$0.16-$0.08-$0.16$205.08 million$199.22 million
2/13/2025Q4 2024
Organon & Co. stock logo
OGN
Organon & Co.
$0.92$0.83-$0.09$0.42$1.57 billion$1.59 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
$1.127.72%+25.99%33.63%N/A
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A

Latest OGN, SMMT, ITCI, and MRNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/13/2025
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.287.3%2/24/20252/24/20253/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/A
7.66
7.51
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62
Organon & Co. stock logo
OGN
Organon & Co.
17.73
1.70
1.21
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
N/A
8.31
8.31

Institutional Ownership

CompanyInstitutional Ownership
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
92.33%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Organon & Co. stock logo
OGN
Organon & Co.
77.43%
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.60%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Organon & Co. stock logo
OGN
Organon & Co.
1.40%
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
88.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
560106.52 million103.56 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.62 million324.40 millionOptionable
Organon & Co. stock logo
OGN
Organon & Co.
10,000257.95 million253.93 millionNot Optionable
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
110737.68 million86.28 millionOptionable

Recent News About These Companies

Citigroup Upgrades Summit Therapeutics (BMV:SMMT)
Citigroup Upgrades Summit Therapeutics (SMMT)
Summit Therapeutics Inc. stock logo
Summit Therapeutics (NASDAQ:SMMT) Upgraded at Citigroup
Summit Therapeutics (NASDAQ:SMMT) Raised to "Buy" at Citigroup
Why Summit Therapeutics Stock Slipped Today
Summit Therapeutics upgraded ahead of lung cancer trial data readout
Summit Therapeutics initiated with an Overweight at Cantor Fitzgerald
Summit Therapeutics (SMMT) Gets a Buy from Cantor Fitzgerald

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Intra-Cellular Therapies stock logo

Intra-Cellular Therapies NASDAQ:ITCI

$131.81 +0.06 (+0.05%)
Closing price 04:00 PM Eastern
Extended Trading
$131.84 +0.03 (+0.03%)
As of 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Moderna stock logo

Moderna NASDAQ:MRNA

$31.12 -1.00 (-3.11%)
Closing price 04:00 PM Eastern
Extended Trading
$31.06 -0.05 (-0.18%)
As of 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$14.52 -0.05 (-0.31%)
Closing price 03:59 PM Eastern
Extended Trading
$14.53 +0.01 (+0.10%)
As of 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$20.32 -0.28 (-1.36%)
Closing price 04:00 PM Eastern
Extended Trading
$20.33 +0.01 (+0.05%)
As of 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.